Zhejiang Shengda Pharm Market Cap ($313.40 Million)
Market Cap & Net Worth: Zhejiang Shengda Pharm (603079)
Zhejiang Shengda Pharm market cap. Zhejiang Shengda Pharm (SHG:603079) has a market capitalization of $313.40 Million (CN¥2.14 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #14283 globally and #4252 in its home market, demonstrating a -0.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shengda Pharm's stock price CN¥11.33 by its total outstanding shares 189029624 (189.03 Million). Also see Zhejiang Shengda Pharm (603079) cash conversion ratio for how efficiently the company converts equity into cash flow.
Zhejiang Shengda Pharm Market Cap History (2017–2026)
Zhejiang Shengda Pharm market cap history from 2017 to 2026. Data shows growth from $701.98 Million to $313.40 Million (0.81% CAGR). Check latest Zhejiang Shengda Pharm stock price today for real-time trading data and today's change.
Zhejiang Shengda Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shengda Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Zhejiang Shengda Pharm annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.58x
Zhejiang Shengda Pharm's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Zhejiang Shengda Pharm's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $701.98 Million | $508.56 Million | $72.61 Million | 1.38x | 9.67x |
| 2018 | $305.06 Million | $492.71 Million | $44.54 Million | 0.62x | 6.85x |
| 2019 | $756.04 Million | $519.15 Million | $47.03 Million | 1.46x | 16.08x |
| 2020 | $576.52 Million | $867.31 Million | $197.44 Million | 0.66x | 2.92x |
| 2021 | $470.87 Million | $789.73 Million | $75.76 Million | 0.60x | 6.22x |
| 2022 | $345.49 Million | $738.02 Million | $31.48 Million | 0.47x | 10.97x |
| 2023 | $403.02 Million | $727.41 Million | -$54.06 Million | 0.55x | N/A |
| 2024 | $372.59 Million | $827.40 Million | $29.42 Million | 0.45x | 12.66x |
| 2025 | $490.15 Million | $844.54 Million | $62.16 Million | 0.58x | 7.89x |
Competitor Companies of 603079 by Market Capitalization
Companies near Zhejiang Shengda Pharm in the global market cap rankings as of November 8, 2026. Also see Zhejiang Shengda Pharm total assets for a full breakdown of the balance sheet.
Key companies related to Zhejiang Shengda Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Zhejiang Shengda Pharm (2017–2026)
Market capitalization of Zhejiang Shengda Pharm from 2017 to today. Between 2017 and today, Zhejiang Shengda Pharm's market cap moved from $701.98 Million to $ 313.40 Million, with a yearly change of 0.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥313.40 Million | -36.06% |
| 2025 | CN¥490.15 Million | +31.55% |
| 2024 | CN¥372.59 Million | -7.55% |
| 2023 | CN¥403.02 Million | +16.65% |
| 2022 | CN¥345.49 Million | -26.63% |
| 2021 | CN¥470.87 Million | -18.33% |
| 2020 | CN¥576.52 Million | -23.75% |
| 2019 | CN¥756.04 Million | +147.83% |
| 2018 | CN¥305.06 Million | -56.54% |
| 2017 | CN¥701.98 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Zhejiang Shengda Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $313.40 Million USD |
| MoneyControl | $313.40 Million USD |
| MarketWatch | $313.40 Million USD |
| marketcap.company | $313.40 Million USD |
| Reuters | $313.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.